Myocardial Infarction is also known as heart attack. Heart attack occurs when one of the coronary arteries of the heart becomes suddenly blocked or has extremely slow blood flow.
The formation of a blood clot is the most common cause of a sudden blockage in a coronary artery (thrombus). The blood clot usually forms inside a coronary artery that has already been narrowed by atherosclerosis, a condition in which fatty deposits (plaques) accumulate along the inside wall of the artery.
Chest discomfort, pain, or discomfort in the upper body, shortness of breath, sweating, indigestion, dizziness, or extreme weakness, and anxiety are all symptoms of a heart attack. ECG and blood tests are conducted to diagnose heart attack. Drugs such as vasodilators, aspirin, and beta blockers are used to treat heart attack.
Market Dynamics
Market players and non-profit organizations are focused on initiatives related to heart attack, which is expected to contribute to the growth of the global myocardial infarction market over the forecast period. For instance, on May 17, 2021, the American College of Cardiology (ACC), a non-profit medical association, announce d that its’ Global Heart Attack Treatment Initiative (GHATI) had measurable positive effects on heart attack care delivery in low-and middle-income countries. The initiative was launched in 2019 with the goal of improving heart attack outcomes in low and middle-income countries by encouraging adherence to medical therapy based on guidelines.
Market players are focusing on product launches which is expected to strengthen their position in the global myocardial infarction market. For instance, on June 1, 2020, AstraZeneca plc., a leading international biopharmaceutical company, announced that its' drug Brilinta (ticagrelor) have been approved by the U.S. Food and Drug Administration (FDA), to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.
Market players and government organizations are involved in expanding their global presence by adopting strategies such as acquisitions and partnerships, which is expected to drive the growth of the global myocardial infarction market. For instance, on October 4, 2020, Amgen Inc., a multinational biotechnology company, announced a new collaboration with two National Health Service (NHS) organizations in the UK: the North West Coast Innovation Agency and Imperial College Health Partners. This collaboration will aid in the fight against the "silent killer" of high cholesterol along the North West Coast of England, an area plagued by heart attacks, strokes, and premature death by cardiovascular diseases.
Key features of the study:
- This report provides an in-depth analysis of global myocardial infarction market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global myocardial infarction market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global myocardial infarction market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global myocardial infarction market.
Detailed Segmentation:
- Global Myocardial Infarction Market, By Drug Class:
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin-receptor Blockers
- Analgesics
- Thrombolytics
- Global Myocardial Infarction Market, By Route of Administration:
- Global Myocardial Infarction Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Myocardial Infarction Market, By Region:
- North America
- By Drug Class:
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin-receptor Blockers
- Analgesics
- Thrombolytics
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drug Class:
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin-receptor Blockers
- Analgesics
- Thrombolytics
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class:
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin-receptor Blockers
- Analgesics
- Thrombolytics
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class:
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin-receptor Blockers
- Analgesics
- Thrombolytics
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class:
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin-receptor Blockers
- Analgesics
- Thrombolytics
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class:
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin-receptor Blockers
- Analgesics
- Thrombolytics
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Bristol-Myers Squibb Co *
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bayer AG
- Johnson & Johnson Services Inc.
- Sanofi S.A.
- Novartis International AG
- AstraZeneca plc.
- Daiichi Sankyo Co Ltd
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Merck KGaA.
“*” marked represents similar segmentation in other categories in the respective section.
